相关实验视频

Updated: Jun 22, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

针对急性髓性白血病的表观遗传基因差异化疗法

Edurne San José-Enériz^1,2, Naroa Gimenez-Camino^1,2, Obdulia Rabal³

¹Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain.

Nature communications

|July 2, 2024

概括

两种新型的 lysine deacetylase 抑制剂,CM-444 和 CM-1758,在低剂量下,在所有急性髓性白血病亚型中有效促进髓性分化. 这些化合物通过向关键分化途径,为急性髓性白血病治疗提供了一个有希望的新途径.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

尽管有新型疗法,急性髓性白血病 (AML) 的结果仍然很差,这凸显了改善治疗方法的迫切需要.
诱导差异化疗法在急性肌肉细胞白血病中是成功的,但需要在其他AML亚型中进行探索.

研究的目的:

识别和描述促进所有AML亚型的髓状细胞分化的新型药物.
研究这些药物的作用机制,重点关注表观遗传修饰.

主要方法:

选和表征氨酸脱乙酶抑制剂 (CM-444和CM-1758) 的情况.
在低剂量,非细胞毒性剂量下,对AML细胞系中髓状细胞分化诱导的评估.
乙组分析以确定由抑制剂调节的蛋白质标和途径.

主要成果:

CM-444和CM-1758在所有测试的AML亚型中都表现出诱导髓状细胞分化的能力.
这些抑制剂在低度的非细胞毒性度下有效,使其与商业素脱乙酶抑制剂区别开来.
在增强剂-促进剂调节复合体内对非歇斯顿蛋白进行治疗调节的乙化,包括odomain蛋白.

结论:

CM-444和CM-1758代表了针对广泛的急性髓性白血病亚型的潜在基于差异化的治疗药物.
该机制涉及关键调节蛋白的乙化,增强转录因子对于差异化疗法至关重要.
这些发现表明,对于治疗急性髓性白血病,有希望的新策略.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

相关概念视频

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Forced Transdifferentiation

Forced Transdifferentiation

Transdifferentiation, also known as lineage reprogramming, was first discovered by Selman and Kafatos in 1974 in silkmoths. They observed that the moths’ cuticle-producing cells transformed into salt-producing cells. Many such cases of natural transdifferentiation occur in organisms. In humans, pancreatic alpha cells can become beta cells. In newts, the loss of the eye’s lens causes the pigmented epithelial cells to transdifferentiate into the lens cells.
Artificial...